XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|73|5-6|298-304

ISSN： 0030-2414

Source： Oncology, Vol.73, Iss.5-6, 2008-05, pp. : 298-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

By Maniadakis Nikos   Fragoulakis Vasilios   Pectasides Dimitrios   Fountzilas George  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 797-805

Informa Healthcare

Access to resources Recommend Favorite

Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 229-236

Karger

Access to resources Recommend Favorite

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4145-4153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment Options for Advanced Colorectal Cancer Continue to Improve

By  

Oncology Research and Treatment, Vol. 22, Iss. 5, 1999-11 ,pp. : 372-373

Karger

Access to resources Recommend Favorite